IFN‐I enhances tumor‐associated antigen presentation, suppresses the activity of protumorigenic regulatory T cells (Treg cells) and/or myeloid‐derived suppressor cells (MDSCs), and enhances effector CD8+ T‐cell and Th1 function [145]. Here, CD8A is linked to neoplasm.